ACTA ENDOCRINOLOGICA (BUC)

Context. It is well known that thyroid hormones are important, being involved in affects the metabolism of carbohydrate, protein, lipids. The relationship between thyroid hormones and lipid metabolism is the focus of recent research. Objective. To investigate the relationship between subclinical hypothyroidism and lipid metabolism in women. Design. We conducted an epidemiological survey of thyroid diseases among women in Northeast China from September 2014 to December 2014. Subjects and Methods. A total of 1397 women underwent physical examinations and laboratory tests for thyroid function and lipid metabolism. Results. We found that the detection rate of subclinical hypothyroidism was 13.03%. Patients with subclinical hypothyroidism showed significantly higher levels of triglyceride (1.69±1.9 vs. 1.45±1.4) and the risk of hyper triglyceridemia in women with thyroid stimulating hormone (TSH) levels ≥10mIU/L was 4.96-fold higher compared with that in the normal population (P<0.01). Conclusion. Disorders of lipid metabolism in women with subclinical hypothyroidism show a direct correlation with the level of TSH, and the risk of hyper triglyceridemia is significantly increased when the level of TSH ≥10mIU/L.

-

Introduction. Pituitary adenomas (PA) are the third most common intracranial tumors, with an incidence rate of 10-15%. More than half are invasive, infiltrating adjacent structures. The primary objective of this project was to determine whether MGMT expression is associated with the invasiveness of PA. Material and Method. All patients who underwent surgical decompression consecutively between 2007- 2012 were included. All data were obtained from the case records. Formalin-fixed paraffin-embedded (FFPE) tissue specimens were stained with hematoxylin and eosin (HE) and then examined via light microscope. Paraffin blocks that lacked necrosis and hemorrhage were chosen for histologic examination. In addition to an immunoprofile battery that consisted of Ki-67 and p53, MGMT, S-100 and Pan-CK were evaluated as well. Results. The subjects included 25 women and 15 men. The mean age was 48.9 ± 14.5 years. Of these, 63% of cases involved the invasion of adjacent structures. Of the PA, 17 (42%) were non-functioning pituitary adenomas (NFPA). There was a statistically significant relationship between the invasiveness and Ki-67, p53, MGMT expression, and prolactinoma. Gonodotropinomas were mostly non-invasive. FPAs presented invasive features more frequently than NFPAs. Pan-CK was positive in GH-secreting adenomas but negative in FSH- and LH-secreting adenomas. Conclusion. Ki-67 and p53 in lower expression level can be used for evaluating invasiveness but not for recurrence. MGMT expression can be a useful IHC indicator for invasiveness. However, Pan-CK cannot be used for invasiveness or aggressiveness.

-

recently. However, the nature of the signals that may connect body fat/muscle tissues with the central nervous system governing energy homeostasis remains to be elucidated. Objective. The present study was designed to investigate the effects of peripheral kisspeptin-10 administration on irisin release in human males. Subjects and methods. Kisspeptin-10 was administered to normal weight (n=8) and obese (n=8) men. Sequential blood sampling was performed for 30 minutes pre and 210 minutes post kisspeptin injection at 30 minutes interval. ELISA kit was used to detect plasma irisin levels. Results. There is a significant (P<0.0001) effect of Kisspeptin-10 administration on irisin release in both normal weight and obese participants. Mean irisin levels (96.24 ± 1.351 ng/mL) at 210 minutes were significantly (P<0.0001) enhanced as compared to pre-kisspeptin (59.18 ± 4.815 ng/ mL) in normal weight subjects. In obese subjects mean irisin levels (75.76 ± 4.06 ng/mL) were significantly (P<0.0001) elevated at 180 minutes post-kisspeptin when compared with pre-kisspeptin irisin levels (41.28 ± 2.89 ng/mL). Conclusion. Our findings suggest that kisspeptin may have a novel therapeutic potential to induce irisin release in humans which may have anti-obesity effects.

Introduction. Subtypes of nonfunctioning pituitary adenomas which may differentiate into functioning adenomas are silent corticotroph adenomas (SCA). These are pituitary tumors positive on immunohistochemical staining for ACTH, but without clinical evidence of Cushing’s disease. Case report. FG, a 50 years old man was twice operated for compressive non secreting pituitary macroadenoma (NFPA). After the first surgery he developed hypopituitarism and needed replacement therapy for all the hormonal lines. After the second surgery he rapidly developed the clinical features of Cushing’s syndrome. Hormonal dosages showed: the absence of the circadian rhythm of cortisol, high ACTH level and the lack of suppression at 1 mg overnight and high dose Dexamethasone suppression tests. The immunohistochemistry of the previously resected pieces confirmed the diagnosis of a silent corticotroph adenoma. The patient was referred for conventional antitumoral radiotherapy associated with Cabergoline, then with Ketoconazole treatment. As the high levels of cortisol recurred, he was subjected to bilateral adrenalectomy. Conclusions. We present the rare case of a silent corticotroph macroadenoma which became hypersecreting after two pituitary adenomectomies. SCA may represent another entity in the spectrum of Cushing’s syndrome that must be evoked in the cases of pituitary macroadenomas thought to be non-functional.

treatment of postmenopausal osteoporosis. It has estrogen agonist effects on bone and on surrogate markers of cardiovascular risk, but estrogen antagonist effects on breast and endometrium. It inhibits bone resorption and decreases bone turnover, increases bone mineral density and reduces the risk of vertebral fractures in postmenopausal women.\r\nObjectives: The main endpoint of our study was to evaluate the effect of raloxifene therapy (60 mg/day) on biochemical markers of bone turnover in romanian osteoporotic postmenopausal women. Secondary endpoints were the effect on bone mineral density (BMD), body mass composition and lipid profile.\r\nMaterials and methods: We performed a longitudinal, prospective, open study, investigating 29 postmenopausal white women with osteoporosis (Group 1) aged 56.9?7.8 years (mean ? SD) and in addition a control group of 29 premenopausal healthy white women (Group 2) with a mean age of 35.10 ? 7.8 years. The diagnosis of osteoporosis was established by dual-energy x-ray absorptiometry. We appreciated in both groups the bone turnover, measuring a marker of bone resorption: serum beta CrossLaps and a marker of bone formation: serum osteocalcin. We determined also the lipid profile: plasma cholesterol (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL) and triglycerides (mg/dL) in all patients. Osteoporotic women received raloxifene 60 mg/day for one year. Biochemical bone markers, lipid profile and body composition have been evaluated at 3, 6 and 12 months of treatment and BMD was performed at 6 and 12 months of therapy.\r\nResults: Postmenopausal osteoporotic women showed an increased bone turnover in comparison with premenopausal women, with statistically significant increased serum values of both resorption and formation biochemical bone markers: respectively 0.48?0.2 vs 0.23?0.1 ng/mL for beta CrossLaps and 27.94?12.1 vs 17.30?8.9 ng/mL for osteocalcin, p<0.001. Raloxifene therapy for three months reduced significantly both bone resorption and formation: 0.36 ? 0.2 vs 0.48 ? 0.2 ng/mL, p< 0.005 for beta CrossLaps and 22.03 ? 10.1 vs 27.94 ?12.1 ng/mL, p< 0.001 for osteocalcin. After 3, 6 and 12 months of therapy with raloxifene the bone markers were statistically significant reduced: -21.2%, -20.4% and respectively -31.6% for osteocalcin and -25%, -39.6% and respectively -50% for beta CrossLaps (p< 0.01). After six months of therapy, serum levels of beta CrossLaps were reduced to premenopausal range (0.29 ? 0.1 vs. 0.23 ? 0.1 ng/mL, p=ns). Total cholesterol and LDL-C were reduced after 12 months (p< 0.03), with no increase in triglycerides and at the same time body mass composition was unchanged.\r\nConclusions: Our results suggest that raloxifene reduces as early as three months the bone turnover in postmenopausal osteoporosis. It reduces bone turnover in premenopausal range after only six months of therapy, for the bone resorption (beta CrossLaps) and after 12 months for bone formation (osteocalcin). In addition raloxifene treatment has favorable effects on BMD and lipid profile, proving safety and a stable body mass composition.

Background. Cerebral vein and sinus thrombosis (CVT) is less encountered, compared to arterial stroke. Commonly witnessed symptoms are headache, nausea, vomiting, confusion, aphasia, seizures, cranial nerve dysfunction and motor or sensorial deficits. The diagnosis is accurately determined by the help of MRI and MR venography. Multiple risk factors associated with CVT are present. Venous thrombosis tends to occur when there is an imbalance between prothrombotic and thrombolytic processes.\r\nCase report. In this report, a patient with CVT extending from left transverse and sigmoid sinuses to jugular vein and diagnosed with diabetes mellitus (DM) during this period\r\nwas discussed in light of literature. The 55-year-old man was evaluated in the neurology clinic with the complaints of headache, nausea, vomiting and blurred speech. On neurologic examination, he was diagnosed with sensorial aphasia and consequently, with DM over the hospital stay. On the cranial MR venography, CVT thrombosis was detected, extending from transverse and sigmoid sinuses to internal jugular vein. Decreased level of protein C and shortage of aPTT were\r\nfound. Anticoagulant treatment was carried out. All complaints were improved.\r\nConclusion. In our subject, the existence of decreased protein C and shortage of APTT, along with DM, is a situation to increase hypercoagulability and the risk of cerebral vein and sinus thrombosis.

Aims. To investigate the changes in the miRNAs and mRNAs expressed in the liver upon induction of “hyperresistinemia”. Methods. We identified mRNA and miRNAs that were differentially expressed between normal and resistin-treated liver tissue using microarrays. Expression was validated using quantitative RT-PCR (qRT-PCR). The putative targets and pathways of the differentially expressed miRNAs and mRNAs were investigated, respectively, using various computational algorithms. In addition, the interactions between differentially expressed miRNAs and mRNAs were analyzed. Results. After the filtration of the signals below the threshold level, we identified 34 miRNAs and 875 genes with expression levels different by more than 1.5-fold and 2.0-fold, respectively, between the two groups. These observations were confirmed by qRT-PCR. Bidirectional prediction analyses showed that the differentially expressed miRNAs may be inversely regulated by their predicted targets. Conclusion. Hyperresistinemia results in changes in the miRNAs and mRNAs expressed in the liver.